STOCKS TELEGRAPH

Tag: TLSA stock

  • Positive Clinical Results: Tiziana Life Sciences PLC (TLSA) Stock Rising in Early Trading.

    Positive Clinical Results: Tiziana Life Sciences PLC (TLSA) Stock Rising in Early Trading.

    Tiziana Life Sciences PLC (TLSA) is a late-stage biotherapeutics enterprise focused on the development of groundbreaking therapeutics. The company’s nasal, and oral therapies have an edge over intravenous delivery. Two lead product candidates of the company include intranasal foralumab and milciclib.

    The price of TLSA stock during the early trading of March 10, 2022, was last checked to be $0.96 with a vertical gain of 25.27%.

    TLSA: Events and Happenings

    On March 10, 2022, TLSA reported optimistic clinical results in the treatment of Secondary Progressive Multiple Sclerosis, following the conclusion of six months of dosage with foralumab. Biological and clinical developments were observed in the patient along with good tolerability using the company’s innovative immunotherapeutics.

    On March 01, 2022, TLSA updated on its publication of data of the highly prognostic potential of StemPrintER for risk of distant reappearance in breast cancer patients in the European Journal of Cancer. On February 10, 2022, TLSA announced its Executive management’s participation at the Virtual BIO CEO & Investor Conference 2022 held on February 14-15, 2022.

    On February 04, 2022, TLSA informed the press about the modified submission of IND application of foralumab to the FDA for its assessment in patients with Crohn’s Disease.

    TLSA: Key Financials

    On September 24, 2021, TLSA reported its interim financial statement for the first half of 2021 ended June 30, 2021. Some of the key aspects are as follows.

    EPS

    Basic and diluted loss attributed to the equity owners per share in H1 2021 was reported to be £12.5 million or 7.4 pence comparable to £3.91 million or 2.6 pence in the same half of 2020. The company noted a considerable gain in its loss over the year.

    Conclusion

    TLSA stock dropped by 82% from the past year as the pandemic laid the financial conditions down globally. Recently, in the early trading, the company’s stock showed signs of improvement as it proclaimed positive clinical outcomes for foralumab.

  • The Reason Why Tiziana Life (TLSA) Stock Jumped 12% In Premarket?

    Tiziana Life Sciences PLC (TLSA) shares are trading at $2.67in premarket trading today, up 12.18%. Last trading session, Tiziana stock fell -7.03% to $2.38. TLSA stock traded 0.37 million shares, which is below the average daily trading volume of 0.43 million shares over the last 50 days.

    TLSA stock has gained 3.03% in the last five days, but has gained 4.39% over the last month. Following a move of treating Covid-19 in-home, TLSA stock is rising.

    What was the inspiration behind TLSA’s solution?

    A UK biotech company, Tiziana is dedicated to discovering and developing new molecules for treating cancer and immune diseases. Milciclib (a CDK inhibitor) is one of several drugs TLSA is developing, including Foralumab for Multiple Sclerosis, Crohn’s Disease, and COVID-19. Formulab is a fully human second generation anti-CD3 monoclonal antibody developed exclusively by TLSA is currently being studied in clinical trials.

    To achieve further clinical development of foralumab as a nasal spray, Tiziana has submitted a grant to the UK COVID Therapeutics Advisory Panel (UK-CTAP), announced TLSA today.

    • As an innovative “Take Home” therapy for non-hospitalized COVID-19 patients, TLSA’s Formulab is a fully human anti-CD3 monoclonal antibody.
    • The TLSA’s move followed a UK government request for proposals to study home-based therapies that would reduce hospitalizations.
    • It is imperative that Foralumab be further developed in patients with Covid-19 with nasal administration.

    TLSA’s other initiatives include:

    A separate clinical trial is also being prepared by Tiziana (TLSA) in Brazil involving hospitalized patients with COVID-19. A key objective of this study by TSLA is to determine whether patients hospitalized with severe inflammation might benefit from nasally administered Foralumab.

    In addition to the COVID-19 variants identified in South Africa, Brazil, the UK, and India, nasal administration with Foralumab has the possibility of being useful for the treatment of other COVID-19 variants.

  • Tiziana Life Sciences Inc. (TLSA) stock rises in the current market trading. Why is it so?

    Tiziana Life Sciences Inc. (TLSA) stock surges by 9.06% in the current market trading session after TLSA stock announced the positive progress of the Foralumab program, which is designed to counter COVID-19 and secondary progressive multiple sclerosis. Tiziana Life Sciences plc is a dual-listed biotechnology firm specializing in the research and development of novel molecules to fight diseases like cancer, inflammation, and other infectious diseases in humans.

    What is happening?

    TLSA stock has declared that the US Food and Drug Administration (FDA) has approved the use of Foralumab, a completely human anti-CD3 monoclonal antibody, in a secondary progressive multiple sclerosis (SPMS) patient at Harvard University’s Brigham and Women’s Hospital (BWH), Boston, MA. This is the first time a nasally administered antibody will be provided to a patient with SPMS, and it will be handled under an Individual Patient Expanded Access IND. The treatment will begin in the second quarter of 2021 and will last for six months.

    To test microglial imaging, researchers at BWH will perform comprehensive routine protection, neurological, imaging, and PET studies on this patient. Normal investigations at the BWH will include the modification of immunological and neurodegenerative indicators.

    Previous record of Phase 1 Trial

    Tiziana previously completed a Phase 1 trial in healthy subjects with a single-site, double-blind, placebo-controlled, multiple ascending dose (MAD) one time in a day dosing for 5 days with nasally administered Foralumab. At doses up to 250 mg, the treatment was well received, with no drug-related adverse effects recorded. Professor Howard of BHW invented nasal foralumab.

    Also,

    TLSA had previously confirmed that the Clinical Trial of Nasal Administration with Foralumab in COVID-19 patients in Brazil had yielded promising results. Nasally administered Foralumab at 100 mg/day for a 10-day treatment period was found to be well-tolerated, with no serious adverse effects reported. Clinical evidence suggested that the procedure reduced lung inflammation significantly. This indicates that the recent development is expected to raise the progress graph for TLSA.